Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina
Light chain (AL) amyloidosis is a form of systemic amyloidosis, causing organ dysfunction, mainly affecting the heart and kidney. Patient-tailored and risk-adapted decision making is critical in AL amyloidosis management. There is limited real-world evidence data from Argentina and Latin America reg...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612475/ https://www.ncbi.nlm.nih.gov/pubmed/36301970 http://dx.doi.org/10.1371/journal.pone.0274578 |
_version_ | 1784819778600304640 |
---|---|
author | Posadas-Martinez, Maria Lourdes Aguirre, María Adela Brulc, Erika Saez, Maria Soledad Sorroche, Patricia Machnicki, Gerardo Fernandez, Mariana Nucifora, Elsa Mercedes |
author_facet | Posadas-Martinez, Maria Lourdes Aguirre, María Adela Brulc, Erika Saez, Maria Soledad Sorroche, Patricia Machnicki, Gerardo Fernandez, Mariana Nucifora, Elsa Mercedes |
author_sort | Posadas-Martinez, Maria Lourdes |
collection | PubMed |
description | Light chain (AL) amyloidosis is a form of systemic amyloidosis, causing organ dysfunction, mainly affecting the heart and kidney. Patient-tailored and risk-adapted decision making is critical in AL amyloidosis management. There is limited real-world evidence data from Argentina and Latin America regarding the treatment approaches for AL amyloidosis. This retrospective cohort study aimed to describe the treatment patterns and outcomes in adult patients (>18 years) diagnosed with AL amyloidosis at the Hospital Italiano in Buenos Aires, Argentina, using a 10-yearfollow-up data (June 1, 2010 to May 31, 2019) from the institutional registry of amyloidosis (IRA). The study population had a mean age of 63 years and 54.4% weremale. Heart and kidney were the most frequently affected organs. Of the 90 eligible patients included in the study, 70underwent treatment. Bortezomib-based regimen was the preferred first-line treatment (75.7% patients). Overall,54.4% of the patients presented a deep response (complete or very good partial response). Median overall survival (OS) was 5years, the 1-year OS and progression free survival rates were 80% (95% confidence interval [CI]: 68–87) and 80% (95%CI 68–87)), respectively. This study provides vital real-world evidence for the long-term treatment patterns and survival in a large cohort of AL amyloidosis patients in Argentina. |
format | Online Article Text |
id | pubmed-9612475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-96124752022-10-28 Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina Posadas-Martinez, Maria Lourdes Aguirre, María Adela Brulc, Erika Saez, Maria Soledad Sorroche, Patricia Machnicki, Gerardo Fernandez, Mariana Nucifora, Elsa Mercedes PLoS One Research Article Light chain (AL) amyloidosis is a form of systemic amyloidosis, causing organ dysfunction, mainly affecting the heart and kidney. Patient-tailored and risk-adapted decision making is critical in AL amyloidosis management. There is limited real-world evidence data from Argentina and Latin America regarding the treatment approaches for AL amyloidosis. This retrospective cohort study aimed to describe the treatment patterns and outcomes in adult patients (>18 years) diagnosed with AL amyloidosis at the Hospital Italiano in Buenos Aires, Argentina, using a 10-yearfollow-up data (June 1, 2010 to May 31, 2019) from the institutional registry of amyloidosis (IRA). The study population had a mean age of 63 years and 54.4% weremale. Heart and kidney were the most frequently affected organs. Of the 90 eligible patients included in the study, 70underwent treatment. Bortezomib-based regimen was the preferred first-line treatment (75.7% patients). Overall,54.4% of the patients presented a deep response (complete or very good partial response). Median overall survival (OS) was 5years, the 1-year OS and progression free survival rates were 80% (95% confidence interval [CI]: 68–87) and 80% (95%CI 68–87)), respectively. This study provides vital real-world evidence for the long-term treatment patterns and survival in a large cohort of AL amyloidosis patients in Argentina. Public Library of Science 2022-10-27 /pmc/articles/PMC9612475/ /pubmed/36301970 http://dx.doi.org/10.1371/journal.pone.0274578 Text en © 2022 Posadas-Martinez et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Posadas-Martinez, Maria Lourdes Aguirre, María Adela Brulc, Erika Saez, Maria Soledad Sorroche, Patricia Machnicki, Gerardo Fernandez, Mariana Nucifora, Elsa Mercedes Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina |
title | Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina |
title_full | Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina |
title_fullStr | Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina |
title_full_unstemmed | Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina |
title_short | Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina |
title_sort | treatment patterns and outcomes in light chain amyloidosis: an institutional registry of amyloidosis report in argentina |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612475/ https://www.ncbi.nlm.nih.gov/pubmed/36301970 http://dx.doi.org/10.1371/journal.pone.0274578 |
work_keys_str_mv | AT posadasmartinezmarialourdes treatmentpatternsandoutcomesinlightchainamyloidosisaninstitutionalregistryofamyloidosisreportinargentina AT aguirremariaadela treatmentpatternsandoutcomesinlightchainamyloidosisaninstitutionalregistryofamyloidosisreportinargentina AT brulcerika treatmentpatternsandoutcomesinlightchainamyloidosisaninstitutionalregistryofamyloidosisreportinargentina AT saezmariasoledad treatmentpatternsandoutcomesinlightchainamyloidosisaninstitutionalregistryofamyloidosisreportinargentina AT sorrochepatricia treatmentpatternsandoutcomesinlightchainamyloidosisaninstitutionalregistryofamyloidosisreportinargentina AT machnickigerardo treatmentpatternsandoutcomesinlightchainamyloidosisaninstitutionalregistryofamyloidosisreportinargentina AT fernandezmariana treatmentpatternsandoutcomesinlightchainamyloidosisaninstitutionalregistryofamyloidosisreportinargentina AT nuciforaelsamercedes treatmentpatternsandoutcomesinlightchainamyloidosisaninstitutionalregistryofamyloidosisreportinargentina |